- Cisplatin 80 mg/m2 IV, Day 1, and 5-FU (5-fluorouracil) 800 mg/m2/day IV continuous infusion over 24 hours daily Day 1-5, every 3 weeks for up to 6 cycles
Patients were treated until disease progression or unacceptable toxicity. The median duration of exposure was 5.91 months (range: 0.1 to 47 months) in TEVIMBRA-treated patients.
Serious adverse reactions occurred in 42% of patients receiving TEVIMBRA in combination with chemotherapy. The most frequent serious adverse drug reactions (≥2%) were pneumonia (3.6%), decreased platelet count (3.2%), gastrointestinal hemorrhage (3%), and colitis (2.2%). Fatal adverse reactions occurred in 4.2% of patients who received TEVIMBRA in combination with chemotherapy; events occurring in 2 or more patients were death, sepsis, pneumonia, pulmonary embolism, and respiratory failure.
Permanent discontinuation of TEVIMBRA due to an adverse reaction occurred in 16% of patients. Adverse drug reactions which resulted in permanent discontinuation in ≥1% of patients were death, fatigue, and pneumonitis.
Dosage interruption of TEVIMBRA due to an adverse drug reaction occurred in 49% of patients. Adverse drug reactions which required dosage interruption in ≥2% of patients were decreased platelet count (12%), decreased neutrophil count (10%), neutropenia (6%), decreased white blood cell count (6%), increased AST (4.8%), increased ALT (3.8%), increased blood bilirubin (3%), COVID-19 (3%), thrombocytopenia (2.8%), leukopenia (2.6%), pneumonitis (2.2%), and pneumonia (2%).
The most common (≥20%) adverse reactions, including laboratory abnormalities, for TEVIMBRA in combination with chemotherapy were nausea, fatigue, decreased appetite, anemia, peripheral sensory neuropathy, vomiting, decreased platelet count, decreased neutrophil count, increased aspartate aminotransferase, diarrhea, abdominal pain, increased alanine aminotransferase, white blood cell count decreased, decreased weight, and pyrexia.
Adverse reactions and laboratory abnormalities are listed in Table 7 and Table 8, respectively.
Table 7: Adverse Reactions (≥10%) in Patients with G/GEJ Receiving TEVIMBRA + Chemotherapy with a Difference Between Arms of ≥5% for All Grades or ≥2% for Grades 3 and 4 vs Placebo + Chemotherapy in RATIONALE-305| Adverse Drug Reaction | TEVIMBRA + Chemotherapy (N=498) | Placebo + Chemotherapy (N=494) |
|---|
All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) |
|---|
| General Disorders and Administration Site Conditions |
| Pyrexia | 20 | 1.6 | 14 | 0.6 |
| Skin and Subcutaneous Tissue Disorders |
| Rash Represents a composite of multiple, related preferred terms. | 16 | 1.6 | 7 | 0 |
| Pruritus | 10 | 0.2 | 3.2 | 0 |
| Endocrine Disorders |
| Hypothyroidism | 13 | 0.2 | 2.8 | 0 |
Other Clinically Important Adverse Reactions Occurring in Less Than 10% include:
Stomatitis, infusion-related reaction, dyspnea, hepatitis, hyperthyroidism, pneumonitis, hyperglycemia, myalgia, diabetes mellitus, pancreatitis, arthritis, Sjogren's syndrome, thyroiditis, adrenal insufficiency, hypophysitis, myasthenia gravis, uveitis, myocarditis, pericarditis, colitis, vitiligo, myositis, and nephritis.
Table 8: Select Laboratory Abnormalities Worsening from Baseline Occurring in ≥10% of Patients Receiving TEVIMBRA + Chemotherapy with a Difference Between Arms of ≥5% for All Grades or ≥2% for Grades 3 and 4 vs Placebo + Chemotherapy in RATIONALE-305 | Laboratory Abnormality | TEVIMBRA + Chemotherapy The denominator used to calculate the rate varied from 480 to 494 based on the number of patients with a baseline value and at least one post-treatment value. (N=498) | Placebo + Chemotherapy (N=494) |
|---|
All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) |
|---|
| Abbreviations: ALT = alanine aminotransferase, AST = aspartate amino transferase. |
| Chemistry |
| AST increased | 58 | 6 | 56 | 3 |
| Sodium decreased | 42 | 7 | 36 | 5 |
| ALT increased | 41 | 4.8 | 36 | 2 |
| Potassium decreased | 33 | 9 | 28 | 6 |
| Hematology |
| Lymphocytes decreased | 53 | 12 | 46 | 9 |
Other Clinically Important Laboratory Abnormalities Occurring in <20% include:
Creatinine increased, potassium increased, glucose decreased, sodium increased, lymphocytes increased, hemoglobin increased.
First-Line Treatment of HER2-Positive Unresectable Locally Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (GEA)
The safety of TEVIMBRA in combination with zanidatamab-hrii and chemotherapy for the treatment of GEA was evaluated in 596 patients in HERIZON-GEA-01. Patients received TEVIMBRA 200 mg by intravenous infusion every 3 weeks with zanidatamab-hrii 1800 mg (<70 kg) or 2400 mg (≥70kg ) and investigator's choice of a fluoropyrimidine- and platinum-based chemotherapy (CAPOX or FP), or trastuzumab 8 mg/kg loading dose (Cycle 1 Day 1) followed by 6 mg/kg intravenous infusion every 3 weeks and investigator's choice of CAPOX or FP. Patients were treated until disease progression or unacceptable toxicity [see Clinical Studies (14.3)].
The median duration of exposure was 9.0 months (range: 0.0 to 44.9 months) in TEVIMBRA-treated patients.
Serious adverse reactions occurred in 59% of patients who received TEVIMBRA in combination with zanidatamab-hrii and chemotherapy; the most frequent serious adverse reactions (≥2%) were diarrhea (17%), infusion-related reactions (5%), vomiting (4.8%), hypokalemia (4.4%), acute kidney injury (3.7%), pneumonia (3.7%), nausea (2.4%), decreased appetite (2.4%), and anemia (2.4%). Fatal adverse reactions occurred in 2.4% of patients who received TEVIMBRA in combination with zanidatamab-hrii and chemotherapy including acute kidney injury (N=2), cardiac failure, diarrhea, dehydration, hypovolemic shock, and intestinal obstruction (all N=1).
Permanent discontinuation of TEVIMBRA due to an adverse reaction occurred in 17% of patients. Adverse reactions which resulted in permanent discontinuation in ≥1% of patients were diarrhea or colitis (3.7%), pneumonitis (2.7%), rash (2.0%), and immune-mediated hepatitis (1.3%).
Dosage interruptions of TEVIMBRA due to an adverse reaction occurred in 60% of patients. Adverse reactions which required dosage interruptions in ≥2% of patients were diarrhea, neutrophil count decreased, platelet count decreased, anemia, decreased appetite, hypokalemia, asthenia, COVID-19, fatigue, ejection fraction decreased, influenza, pyrexia, and vomiting.
The most common (≥20%) adverse reactions for TEVIMBRA in combination with zanidatamab-hrii and chemotherapy, including laboratory abnormalities, were: diarrhea (83%), nausea (56%), anemia (47%), decreased appetite (46%), vomiting (44%), hypokalemia (39%), fatigue (37%), rash (36%), decreased neutrophil count (35%), decreased platelet count (31%), peripheral neuropathy (27%), infusion-related reaction (25%), and increased aspartate aminotransferase (21%).
Adverse reactions and laboratory abnormalities are listed in Table 9 and Table 10, respectively.
Table 9: Adverse Reactions (≥10%) With an Increased Incidence (≥5% Increase in All Grades) in Patients Receiving TEVIMBRA in HERIZON-GEA-01| Adverse Reaction Graded per CTCAE version 5. | TEVIMBRA with Zanidatamab-hrii and Chemotherapy N=294 | Trastuzumab with Chemotherapy N=302 |
|---|
All Grades (%) | Grade 3 or higher (%) | All Grades (%) | Grade 3 or higher (%) |
|---|
| Gastrointestinal Disorders |
| Diarrhea Diarrhea includes colitis, diarrhea, enteritis, enterocolitis and enterocolitis hemorrhagic. | 83 | 26 | 53 | 14 |
| Nausea | 56 | 8 | 48 | 3 |
| Vomiting Vomiting includes hematemesis and vomiting. | 44 | 6 | 34 | 4.3 |
| Metabolism and Nutrition Disorders |
| Decreased appetite | 46 | 8 | 36 | 6 |
| General Disorders and Administration Site Conditions |
| Fatigue Fatigue includes asthenia and fatigue. | 37 | 7 | 30 | 6 |
| Skin and Subcutaneous Tissue Disorders | | | | |
| Rash Rash includes rash, rash maculo-papular, dermatitis, palmar plantar erythrodysesthesia syndrome, rash pustular, urticaria, dermatitis acneiform, rash erythematous. | 36 | 5 | 25 | 5 |
| Pruritus | 17 | 0.7 | 3.6 | 0 |
| Injury, Poisoning and Procedural Complications |
| Infusion-related reaction | 25 | 1.7 | 13 | 0.7 |
| Investigations |
| Ejection fraction decreased Ejection fraction decreased includes cardiac failure, ejection fraction decreased, left ventricular dysfunction and right ventricular failure. | 12 | 3.1 | 7 | 1.3 |
Table 10: Select Laboratory Abnormalities ( ≥30%) with an Increased Incidence (at least 5% of all Grades or 2% Grade 3-4) in HERIZON-GEA-01| Laboratory Abnormalities | TEVIMBRA with Zanidatamab-hrii and Chemotherapy N=294 | Trastuzumab with Chemotherapy N=302 |
|---|
All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) |
|---|
| Hematology |
| Hemoglobin decreased | 97 | 19 | 92 | 16 |
| Chemistry |
| Blood calcium decreased | 62 | 1.7 | 56 | 1.7 |
| Potassium decreased | 61 | 27 | 38 | 12 |
| Sodium decreased | 43 | 2 | 35 | 1 |
| Blood magnesium decreased | 42 | 0.3 | 24 | 0 |
| Creatinine increased | 34 | 4.1 | 21 | 2.3 |
Risk Summary
Based on its mechanism of action, TEVIMBRA can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on the use of TEVIMBRA in pregnant women. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death (see Data). Human IgG4 immunoglobulins (IgG4) are known to cross the placental barrier; therefore, tislelizumab-jsgr has the potential to be transmitted from the mother to the developing fetus. Advise pregnant women of the potential risk to a fetus.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Data
Animal Data
Animal reproduction studies have not been conducted with TEVIMBRA to evaluate its effect on reproduction and fetal development. A central function of the PD-1/PD-L1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to the fetus. In murine models of pregnancy, blockade of PD-L1 signaling has been shown to disrupt tolerance to the fetus and to result in an increase in fetal loss; therefore, potential risks of administering TEVIMBRA during pregnancy include increased rates of abortion or stillbirth. As reported in the literature, there were no malformations related to the blockade of PD-1 signaling in the offspring of these animals; however, immune-mediated disorders occurred in PD-1 and PD-L1 knockout mice. Based on its mechanism of action, fetal exposure to tislelizumab-jsgr may increase the risk of developing immune-mediated disorders or altering the normal immune response.
Risk Summary
There is no information regarding the presence of tislelizumab-jsgr in human milk, or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment and for 4 months after the last dose of TEVIMBRA.
Pregnancy Testing
Verify pregnancy status in females of reproductive potential prior to initiating TEVIMBRA [see Use in Specific Populations (8.1)].
Contraception
Females
Advise females of reproductive potential to use effective contraception during treatment with TEVIMBRA and for 4 months after the last dose of TEVIMBRA.
TEVIMBRA as a Single Agent
Of the 255 patients who were treated with TEVIMBRA for previously treated unresectable or metastatic ESCC in the clinical study RATIONALE-302, 98 (38%) were 65 years and older and 13 (5%) were 75 years and older. No overall differences in safety or effectiveness were observed between elderly patients and younger patients.
TEVIMBRA in Combination with Chemotherapy
Of the 324 patients who were treated with TEVIMBRA and platinum-containing chemotherapy as first-line treatment for unresectable advanced or metastatic ESCC in the clinical study RATIONALE-306, 149 (46%) were 65 years and older and 13 (4%) were 75 years and older. No overall differences in safety or effectiveness were observed between elderly patients and younger patients.
Of the 498 patients who were treated with TEVIMBRA in combination with platinum-containing chemotherapy for G/GEJ adenocarcinoma in the clinical study RATIONALE-305, 161 (32%) were 65 years and older, and 28 (6%) were 75 years and older. No overall differences in safety or effectiveness were observed between elderly patients and younger patients.
TEVIMBRA in Combination with Zanidatamab-hrii and Chemotherapy
Of the 302 patients who received TEVIMBRA in combination with zanidatamab-hrii and chemotherapy for GEA, there were 139 (46%) patients 65 years of age and older, 106 (35%) were 65 to 74 years old, and 33 (11%) were 75 years and older.
There was a higher incidence of Grade ≥3 adverse reactions observed in patients 65 years of age and older (87%) as compared to younger patients (80%). The incidence of Grade 3 or 4 diarrhea was higher in patients 65 years and older (32%) compared to patients younger than 65 years (20%). There was an increased incidence of fatal adverse reactions in patients 65 years and older (4.4%), including acute kidney injury (N=2), cardiac failure, dehydration, hypovolemic shock and intestinal obstruction (all N=1), compared to younger patients (0.6%), including diarrhea (N=1).
Distribution
The tislelizumab-jsgr steady-state total volume of distribution is 6.42 L (32.6%).
Elimination
The tislelizumab-jsgr total clearance is 0.153 L/day (29.5%) and the terminal half-life (t½) is 24 days (31%).
Specific Populations
No clinically significant differences in the pharmacokinetics of tislelizumab-jsgr were observed based on age (range: 18 to 90 years), weight (range: 32 to 130 kg), race (White, Asian, or Black), mild to moderate renal impairment (CLcr ≥30 mL/min, estimated by Cockcroft-Gault), mild to moderate hepatic impairment (total bilirubin ≤3 times ULN and any AST, estimated by NCI criteria). The effect of severe hepatic impairment (total bilirubin >3 times ULN and any AST), severe renal impairment (CLcr 15-29 mL/min), or end-stage renal disease (CLcr <15 mL/min) on the pharmacokinetics of tislelizumab-jsgr is unknown.
First-line Treatment of Unresectable or Metastatic Esophageal Carcinoma (ESCC) in Patients Whose Tumors Express PD-L1 (≥1)
The efficacy of TEVIMBRA, in combination with chemotherapy, was evaluated in RATIONALE-306 (NCT03783442), a global, randomized, placebo-controlled, double-blind study in patients with unresectable, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).
Patients were enrolled regardless of their PD-L1 expression level. PD-L1 expression was evaluated at a central laboratory using the Ventana PD-L1 (SP263) assay that identified PD-L1 staining on both tumor and tumor-associated immune cells (Tumor Area Positivity or TAP). A retrospective scoring of tumor PD-L1 status using Combined Positive Score (CPS) was also conducted using the PD-L1–stained tumor specimens used for randomization.
Patients should not have received prior systemic therapy for advanced or metastatic disease. A treatment-free interval of at least 6 months was required if there was prior neoadjuvant/adjuvant therapy with platinum-based chemotherapy. The trial excluded patients who had active leptomeningeal disease or uncontrolled brain metastasis, active autoimmune disease, a medical condition requiring systemic corticosteroids or immunosuppressants, or evidence of fistula or complete esophageal obstruction not amenable to treatment.
Patients were randomized (1:1) to receive either TEVIMBRA 200 mg every 3 weeks or placebo in combination with investigator's choice of chemotherapy (ICC) on a 21-day cycle. Patients received TEVIMBRA until disease progression assessed by the investigator per RECIST v1.1, or until unacceptable toxicity. The chemotherapy doublet regimen consists of:
- Platinum (cisplatin [60 to 80 mg/m2 IV, on Day 1] or oxaliplatin [130 mg/m2 IV, on Day 1]) and a fluoropyrimidine (fluorouracil [750 to 800 mg/m2 IV, on Days 1 to 5] or capecitabine [1000 mg/m2 orally twice daily, on Days 1 to 14])
or
- Platinum (cisplatin [60 to 80 mg/m2 IV, on Day 1 or 2] or oxaliplatin [130 mg/m2 IV, on Day 1 or 2]) and (paclitaxel 175 mg/m2 IV, on Day 1)
Cross-over between treatment arms or between fluoropyrimidine and paclitaxel during the study treatment period was not allowed.
Patient randomization was stratified by geographic region (Asia [excluding Japan] versus Japan versus Rest of World), prior definitive therapy (yes versus no), and investigator choice of chemotherapy (ICC; platinum with fluoropyrimidine versus platinum with paclitaxel).
Tumor assessments were performed every 6 weeks for the first 48 weeks, then every 9 weeks thereafter.
The primary efficacy outcome measure was overall survival (OS) in the Intent-to-Treat (ITT) population. Secondary outcome measures included progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR) as assessed by the investigator per RECIST v1.1. Additional analyses of efficacy outcome measures were also conducted based on PD-L1 TAP ≥1% and CPS ≥1.
A total of 649 patients were randomized. The trial population characteristics were median age 64 years (range: 26 to 84 years), 48% were ≥65 years of age, 87% were male, 75% were Asian, and 24% were White. Eighty-six percent had metastatic disease and 14% had locally advanced disease; 99.8% of patients had histological confirmation of squamous cell carcinoma. Baseline ECOG performance status was 0 (33%) or 1 (67%). Thirty-four percent of patients had tumors that expressed PD-L1 TAP ≥10%, 74% had PD-L1 TAP ≥1%, and 74% had PD-L1 CPS ≥1. Fifty-five percent of patients received platinum (cisplatin or oxaliplatin) and paclitaxel-containing regimens, and 45% received platinum (cisplatin or oxaliplatin) and fluoropyrimidine-containing regimens.
RATIONALE-306 demonstrated a statistically significant improvement in OS for patients randomized to TEVIMBRA in combination with chemotherapy compared to placebo in combination with chemotherapy. Exploratory analysis of OS in the population with TAP <1% population and in the CPS <1 population showed hazard ratios of 1.34 (95% CI 0.73, 2.46) and 1.52 (95% CI 0.81, 2.84), respectively, indicating that the improvement in the ITT population was primarily attributed to the results observed in the subgroup of patients with PD-L1 ≥1.
Efficacy results are shown in Table 11, Figure 1, and Figure 2.
Table 11: Efficacy Results in RATIONALE-306| Endpoint | TEVIMBRA + Chemotherapy (N=231) | Placebo + Chemotherapy (N=250) | TEVIMBRA + Chemotherapy (N=233) | Placebo + Chemotherapy (N=247) |
|---|
| PD-L1 TAP ≥1% | PD-L1 CPS ≥1 |
|---|
| CI = confidence interval; HR = hazard ratio. |
| Overall Survival (OS) |
| Deaths n (%) | 141 (61) | 177 (70.8) | 141 (61) | 175 (71) |
| Median (months) Medians were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley. (95% CI) | 16.8 (15.3, 20.8) | 9.6 (8.9, 11.8) | 16.8 (15.3, 20.8) | 9.6 (8.9, 11.8) |
| HR Estimated by Cox proportional hazards model. (95% CI) | 0.66 (0.53, 0.82) | 0.65 (0.52,0.81) |
| Progression-Free Survival (PFS) |
| Events, n (%) | 152 (66) | 199 (80) | 153 (66) | 195 (79) |
| Median (months) (95% CI) | 7.2 (6.8, 8.5) | 5.5 (4.5, 5.8) | 7.1 (6.8, 8.3) | 5.5 (4.5, 5.8) |
| HR (95% CI) | 0.56 (0.45, 0.70) | 0.57 (0.46, 0.71) |
| Objective Response Rate (ORR) Confirmed responses. |
| Responders, n | 134 | 90 | 134 | 89 |
| ORR, % | 58 | 36 | 58 | 36 |
| 95% CI Exact Clopper-Person-2-sided CI. | (51, 65) | (30, 42) | (51, 64) | (30, 42) |
| Complete response (CR), n (%) | 11 (4.8) | 5 (2) | 11 (4.7) | 5 (2) |
| Partial response, n (%) | 123 (53) | 85 (34) | 123 (53) | 84 (34) |
| Duration of Response (DoR) |
| Median DoR (months) (95% CI) | 7.2 (6.2, 9.6) | 5.7 (4.4, 7.3) | 7.6 (6.6, 9.7) | 5.6 (4.4, 7.3) |
Figure 1: Kaplan-Meier Curve for Overall Survival in RATIONALE-306 (PD-L1 TAP ≥1%)
Figure 2: Kaplan-Meier Curve for Overall Survival in RATIONALE-306 (PD-L1 CPS ≥1)
Efficacy results from the exploratory retrospective analysis with CPS scoring were generally consistent with the efficacy results for TAP subgroups detailed in Table 11 and Figure 1.
Previously Treated Unresectable or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
RATIONALE-302 (NCT03430843) was a multicenter, randomized (1:1), open-label trial in 512 adult patients with unresectable advanced or metastatic ESCC who progressed on or after prior systemic chemotherapy.
Patients were enrolled regardless of their tumor PD-L1 expression level. PD-L1 expression was evaluated at a central laboratory using the Ventana PD-L1 (SP263) assay that identified PD-L1 staining on both tumor and tumor-associated immune cells (TAP). The trial excluded patients who received a prior immune checkpoint inhibitor, had brain or leptomeningeal metastases that were symptomatic or required treatment, active autoimmune disease, a medical condition requiring systemic corticosteroids or immunosuppressants, or apparent tumor invasion of organs adjacent to the esophageal tumor.
Patients were randomized (1:1) to receive either TEVIMBRA 200 mg every 3 weeks or investigator's choice of chemotherapy (ICC), all given intravenously: paclitaxel 135-175 mg/m2 every 3 weeks or 80 to 100 mg/m2 weekly, docetaxel 75 mg/m2 every 3 weeks, or irinotecan 125 mg/m2 on Days 1 and 8 of every 3-week cycle. Patients were treated until disease progression assessed by the investigator or unacceptable toxicity.
Randomization was stratified by geographic region (Asia [excluding Japan] vs Japan vs US/EU), ECOG performance status (0 vs 1), and ICC option. Tumor assessments were conducted every 6 weeks for the first 6 months, then every 9 weeks until disease progression.
The major efficacy outcome measure was overall survival (OS) in the Intent-to-Treat (ITT) population. Additional efficacy outcome measures were investigator-assessed progression-free survival (PFS), overall response rate (ORR), and duration of response (DoR) per RECIST v1.1.
A total of 512 patients were enrolled and randomized to TEVIMBRA (n=256) or ICC (n=256) (irinotecan [46%], paclitaxel [33%], or docetaxel [21%]). Of the 512 patients, 142 (28%) had PD-L1 ≥10%, 222 (43%) had PD-L1 <10%, and 148 (29%) had unknown baseline PD-L1 status.
The trial population characteristics were: median age of 62 years (range: 35 to 86), 38% age ≥65; 84% male; 19% White and 80% Asian; 95% had metastatic disease. All patients had received at least one prior anti-cancer systemic therapy. Baseline ECOG performance status was 0 (25%) or 1 (75%).
RATIONALE-302 demonstrated a statistically significant improvement in OS for patients randomized to TEVIMBRA as compared with ICC. OS results by PD-L1 CPS level (<1 and ≥1) were not studied.
Efficacy results are shown in Table 12 and Figure 3.
Table 12: Efficacy Results in RATIONALE-302 in ITT Population| Endpoint | TEVIMBRA (N=256) | ICC (N=256) |
|---|
| CI = confidence interval, ORR = objective response rate. |
| Overall Survival |
| Deaths n (%) | 197 (77) | 213 (83.2) |
| Median (months) Estimated using Kaplan-Meier method. (95% CI) | 8.6 (7.5, 10.4) | 6.3 (5.3, 7) |
| Hazard ratio Based on Cox regression model stratified by baseline ECOG status and ICC option. (95% CI) | 0.7 (0.57, 0.85) |
| p-value One-sided p-value based on log-rank test stratified by ECOG performance status and ICC option. | 0.0001 |
| Progression-Free Survival |
| Disease progression or death (%) | 223 (87.1) | 180 (70.3) |
| Median (months) (95% CI) | 1.6 (1.4, 2.7) | 2.1 (1.5, 2.7) |
| Hazard ratio (95% CI) | 0.83 (0.67, 1.01) |
| Objective Response Rate Confirmed response. |
| ORR (%) (95% CI) | 15.2 (11.1, 20.2) | 6.6 (3.9, 10.4) |
| Complete response n (%) | 5 (2) | 1 (0.4) |
| Partial response n (%) | 34 (13.3) | 16 (6.3) |
| Duration of Response |
| Median (months) (95% CI) | 10.3 (6.5, 13.2) | 6.3 (2.8, 8.5) |
Figure 3: Kaplan-Meier Curve for Overall Survival in RATIONALE-302 (ITT)
Previously Untreated, Unresectable, or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma in Patients Whose Tumors Express PD-L1 (≥1)
RATIONALE-305 (NCT03777657) was a randomized, multicenter, placebo-controlled, double-blind trial in patients with HER2-negative previously untreated unresectable or metastatic G/GEJ adenocarcinoma.
Patients were enrolled regardless of their tumor PD-L1 expression level, which was evaluated prospectively at a central laboratory using the VENTANA PD-L1 (SP263) assay that identified PD-L1 staining on both tumor and tumor-associated immune cells (TAP). A retrospective scoring of tumor PD-L1 status using Combined Positive Score (CPS) was also conducted using the PD-L1-stained tumor specimens used for randomization.
The trial excluded patients who had active leptomeningeal disease or uncontrolled brain metastasis, and patients with active autoimmune disease or history of autoimmune diseases, or a medical condition requiring systemic corticosteroids or immunosuppressants.
Patients were randomized to receive either TEVIMBRA 200 mg every 3 weeks or placebo in combination with investigator's choice of chemotherapy on a 21-day cycle. TEVIMBRA (or placebo) was administered until disease progression or unacceptable toxicity.
The chemotherapy doublets regimen consisted of:
- CAPOX: Oxaliplatin 130 mg/m2 IV on Day 1 for up to 6 cycles and capecitabine 1000 mg/m2 orally twice daily for 14 consecutive days. Capecitabine treatment could be continued beyond 6 cycles
or
- FP: Cisplatin 80 mg/m2 IV, Day 1, and 5-FU 800 mg/m2/day IV continuous infusion over 24 hours daily Day 1-5. Cisplatin and 5-FU were given for up to 6 cycles
Cross-over between treatment arms was not allowed.
Patient randomization was stratified by geographic region (China [including Taiwan], vs Japan and South Korea vs rest of the world, including US and Europe); PD-L1 expression (PD-L1 TAP score ≥5% vs PD-L1 TAP score <5%); presence of peritoneal metastasis (yes vs no); and ICC option (oxaliplatin plus capecitabine vs cisplatin plus 5-FU).
Tumor assessments were performed every 6 weeks for the first 48 weeks and thereafter approximately every 9 weeks.
The primary efficacy outcome measures were OS in the PD-L1 TAP score ≥5% population and in the Intent-to-Treat (ITT) population. Secondary outcome measures included progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR) as assessed by the investigator per RECIST v1.1. Additional analyses of efficacy outcome measures were also conducted based on PD-L1 TAP ≥1% and CPS ≥1.
A total of 997 patients were randomized. The trial population characteristics were median age 61 years (range: 23 to 86 years), 35% ≥65 years of age, 69% male; 75% Asian, 22% White, and 0% Black or African American. Eighty percent had primary stomach tumor; 89% had PD-L1 TAP ≥1% and 86% had PD-L1 CPS ≥1, and 99% of patients had metastatic disease at baseline. Baseline ECOG performance status was 0 (32%) or 1 (68%). Ninety-three percent of patients received CAPOX and 7% received FP.
RATIONALE-305 demonstrated a statistically significant improvement in OS for patients randomized to TEVIMBRA in combination with chemotherapy compared with placebo plus chemotherapy in the PD-L1 TAP ≥5% population and in the ITT population. Exploratory analyses of OS in the TAP <1% population and in the CPS <1 population showed hazard ratios of 0.98 (95% CI: 0.64, 1.50) and 1.01 (95% CI: 0.66, 1.52) respectively, indicating that the improvement in the ITT population was primarily attributed to the results observed in the subgroup of patients with PD-L1 ≥1.
Efficacy results are summarized in Table 13, Figure 4, and Figure 5.
Table 13: Efficacy Results in RATIONALE-305 | Endpoint | TEVIMBRA + Chemotherapy (N=432) | Placebo + Chemotherapy (N=453) | TEVIMBRA + Chemotherapy (N=420) | Placebo + Chemotherapy (N=434) |
|---|
| PD-L1 TAP ≥1% | PD-L1 CPS ≥1 |
|---|
| Abbreviations: CI = confidence interval, HR = hazard ratio, ORR = objective response rate. |
| Overall Survival |
| Deaths n (%) | 318 (74) | 370 (82) | 308 (73) | 356 (82) |
| Median (months) Medians were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley. (95% CI) | 15 (13.3, 16.7) | 12.8 (12.1, 14.1) | 15.1 (13.6, 17.2) | 12.9 (12.1, 14.1) |
| HR Estimated by Cox proportional hazards model. (95% CI) | 0.78 (0.67, 0.90) | 0.78 (0.67, 0.91) |
| Progression-Free Survival |
| Events, n (%) | 316 (73) | 364 (80) | 303 (72) | 348 (80) |
| Median Based on confirmed response. (months) (95% CI) | 6.9 (5.7, 7.2) | 5.9 (5.6, 6.9) | 7 (5.7, 7.7) | 6.4 (5.6, 6.9) |
| HR (95% CI) | 0.78 (0.67, 0.91) | 0.77 (0.66, 0.90) |
| Objective Response Rate |
| ORR, n | 206 | 186 | 204 | 183 |
| ORR, % | 48 | 41 | 49 | 42 |
| 95% CI (%) Exact Clopper-Pearson 2-sided confidence interval. | (43, 53) | (37, 46) | (44, 53) | (37, 47) |
| Complete response, n (%) | 15 (3.5) | 15 (3.3) | 16 (3.8) | 16 (3.7) |
| Partial response, n (%) | 191 (44) | 171 (38) | 188 (45) | 167 (38) |
| Duration of Response |
| Median (months) (95% CI) | 8.6 (7.8, 10.4) | 7.2 (5.8, 8.3) | 8.6 (7.8, 10.4) | 7.2 (5.8, 8.5) |
Figure 4: Kaplan-Meier Curve for Overall Survival in RATIONALE-305 (PD-L1 TAP ≥1%)
Figure 5: Kaplan-Meier Curve for Overall Survival in RATIONALE-305 (PD-L1 CPS ≥1)
An exploratory subgroup analysis of OS in 40 patients with MSI-H tumors irrespective of PD-L1 status showed a HR of 0.66 (0.3, 1.43).
First-Line Treatment of HER2-Positive (IHC3+/ IHC2+/ISH+) Unresectable Locally Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
The efficacy of TEVIMBRA in combination with zanidatamab-hrii and fluoropyrimidine- and platinum-containing chemotherapy for the treatment of GEA was evaluated in HERIZON-GEA-01 (NCT05152147), a randomized, multicenter, 3-arm, open-label, active-comparator study.
Patients had untreated, unresectable locally advanced/metastatic, HER2-positive (IHC 3+ or IHC 2+/ISH+) per central testing, an ECOG PS of 0 or 1, and adequate organ function, including left ventricular ejection fraction (LVEF) ≥50%. Patients were enrolled regardless of their PD-L1 expression.
Randomization was stratified by geographic region (Asian, EU/North America, Rest of World), HER2 status (3+ IHC staining, 2+ IHC staining with ISH-positivity), and Eastern Cooperative Oncology Group (ECOG) performance status (0, 1).
Patients were randomized to receive one of the following treatment arms, each with investigator's choice of a fluoropyrimidine- and platinum-containing chemotherapy – CAPOX (capecitabine 1,000 mg/m2 administered orally twice a day from the evening of Day 1 to the morning of Day 15 of each 21-day cycle plus oxaliplatin 130 mg/m2 administered intravenously on Day 1 of each 21-day cycle) or FP (5-Fluorouracil 800 mg/m2/day administered as continuous intravenous infusion on Days 1 to 5 of each 21-day cycle plus cisplatin 80 mg/m2 administered intravenously on Day 1 of each 21-day cycle) for at least 6 cycles:
- TEVIMBRA 200 mg administered intravenously with zanidatamab-hrii 1800 mg (for patients with a body weight of <70kg) or 2400 mg (for patients with a body weight ≥70 kg) administered intravenously on Day 1 of each 21-day cycle, or
- Zanidatamab-hrii 1800 mg (for patients with a body weight of <70kg) or 2400 mg (for patients with a body weight ≥70 kg) administered intravenously on Day 1 of each 21-day, or
- Trastuzumab 6 mg/kg administered intravenously on day 1 of each 21-day cycle (8 mg/kg loading dose administered intravenously on Cycle 1, Day 1) (control arm).
Treatment with TEVIMBRA and zanidatamab-hrii continued in each arm until disease progression, unacceptable toxicity, or other discontinuation criteria were met. Efficacy assessments were based on patients randomized to the TEVIMBRA plus zanidatamab-hrii and chemotherapy versus the trastuzumab and chemotherapy arms.
The dual major efficacy endpoints were progression-free survival (PFS) assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and overall survival (OS). Additional efficacy outcome measures included objective response rate (ORR) and duration of response (DoR).
A total of 914 patients were enrolled into the HERIZON-GEA-01 trial with 610 patients randomized to the TEVIMBRA and control arms. Of these patients, 434 had gastric adenocarcinoma, 134 had gastroesophageal junction adenocarcinoma, and 42 had esophageal adenocarcinoma. The trial population characteristics were median age 64 years (range: 21 to 84 years), 47% ≥65 years of age, 79% male; 55% Asian, 40% White, 2% American Indian or Alaskan Native, and 1.6% of other or multiple races; 40% ECOG performance status of 0 or 60% performance status of 1.
HERIZON-GEA-01 demonstrated a statistically significant improvement in OS and PFS for patients randomized to TEVIMBRA plus zanidatamab-hrii and chemotherapy arm, compared with the trastuzumab plus chemotherapy arm.
Efficacy results are shown in Table 14, Figure 6, and Figure 7.
Table 14: Efficacy Results in HERIZON-GEA-01 | TEVIMBRA + Zanidatamab-hrii and Chemotherapy N=302 | Trastuzumab + Chemotherapy N=308 |
|---|
| Abbreviations: CI = confidence interval. |
| Overall Survival Estimates per Kaplan-Meier method. |
| Deaths (%) | 134 (44%) | 170 (55%) |
| Median, months | 26.4 | 19.2 |
| (95% CI) | (21.5, 30.3) | (16.8, 21.8) |
| Hazard ratio (95% CI) Hazard ratio and 95% CIs were calculated stratified by geographic region, HER2 status, and ECOG performance status. | 0.72 (0.57, 0.90) |
| p-value The p-values were calculated by stratified log-rank test. | 0.0043 |
| Progression-Free Survival |
| Number of events (%) | 154 (51%) | 196 (64%) |
| Median, months | 12.4 | 8.1 |
| (95% CI) | (9.8, 18.5) | (7.0, 8.9) |
| Hazard ratio (95% CI) | 0.63 (0.51, 0.78) |
| p-value | <0.0001 |
| Objective Response Rate (ORR) |
| ORR (95% CI) Two-sided 95% exact confidence interval using the Clopper-Pearson method. | 67% (61, 72) | 63% (57, 68) |
| Complete response rate | 20% | 12% |
| Partial response rate | 47% | 50% |
| Duration of Response (DoR) | N=202 | N=193 |
| Median in months (95% CI) | 18.9 (12.1, 37.7) | 8.3 (6.8, 10.1) |
In prespecified exploratory analyses comparing TEVIMBRA + zanidatamab-hrii + chemotherapy (Arm C) and trastuzumab + chemotherapy (Arm A) in the HER2 IHC3+ population, the PFS HR was 0.54 (95% CI: 0.43, 0.69), with a median 16.1 months (95% CI: 10.9, 22.0) in Arm C and 7.6 months (6.9, 8.5) in Arm A; the OS HR was 0.70 (95% CI: 0.55, 0.91), with a median 27.3 months (95% CI: 22.3, NE) in Arm C and 19.8 months (95% CI: 16.2, 22.8) in Arm A. In the HER2 IHC2+/ISH+ population, the PFS HR was 1.08 (95% CI: 0.65, 1.78), with a median 8.6 months (95% CI: 6.7, 11.1) in Arm C and 10.0 months (95% CI: 6.9, 18.4) in Arm A; the OS HR was 0.83 (95% CI: 0.50, 1.39), with a median 21.5 months (95% CI: 16.0, 26.4) in Arm C and 18.7 months (95% CI: 13.6, 23.1) in Arm A.
Figure 6: Kaplan-Meier Plot of Overall Survival in HERIZON-GEA-01
Figure 7: Progression Free Survival Curve in HERIZON-GEA-01
How Supplied
TEVIMBRA injection is a clear to slightly opalescent, colorless to slightly yellow solution supplied in a carton containing one single-dose vial, available as follows:
| Strength | NDC |
|---|
| 100 mg/10 mL (10 mg/mL) | 72579-121-01 |
| 150 mg/15 mL (10 mg/mL) | 72579-125-00 |
Immune-Mediated Adverse Reactions
Inform patients of the risk of immune-mediated adverse reactions that may be severe or fatal, may occur after discontinuation of treatment, and may require corticosteroid treatment and interruption or discontinuation of TEVIMBRA. These reactions may include:
- Pneumonitis: Advise patients to contact their healthcare provider immediately for new or worsening cough, chest pain, or shortness of breath [see Warnings and Precautions (5.1)].
- Colitis: Advise patients to contact their healthcare provider immediately for diarrhea, or severe abdominal pain [see Warnings and Precautions (5.1)].
- Hepatitis: Advise patients to contact their healthcare provider immediately for jaundice, severe nausea or vomiting, pain on the right side of the abdomen, or easy bruising or bleeding [see Warnings and Precautions (5.1)].
- Endocrinopathies: Advise patients to contact their healthcare provider immediately for signs or symptoms of hypophysitis, adrenal insufficiency, hypothyroidism, hyperthyroidism, thyroiditis, or Type 1 diabetes mellitus [see Warnings and Precautions (5.1)].
- Nephritis: Advise patients to contact their healthcare provider immediately for signs or symptoms of nephritis [see Warnings and Precautions (5.1)].
- Dermatologic Adverse Reactions: Advise patients to contact their healthcare provider immediately for any signs or symptoms of severe skin reactions, SJS, TEN, or DRESS [see Warnings and Precautions (5.1)].
- Other Immune-Mediated Adverse Reactions:
- Advise patients that immune-mediated adverse reactions can occur and may involve any organ system, and to contact their healthcare provider immediately for any new or worsening signs or symptoms [see Warnings and Precautions (5.1)].
- Advise patients of the risk of solid organ transplant rejection and other transplant (including corneal graft) rejection and to contact their healthcare provider immediately for signs or symptoms of organ transplant rejection [see Warnings and Precautions (5.1)].
Infusion-Related Reactions
Advise patients to contact their healthcare provider immediately for signs or symptoms of infusion-related reactions [see Warnings and Precautions (5.2)].
Complications of Allogeneic Hematopoietic Stem Cell Transplantation Complications
Advise patients of potential risk of post-allogeneic hematopoietic stem cell transplantation complications (HSCT) [see Warnings and Precautions (5.3)].
Embryo-Fetal Toxicity
Advise females of reproductive potential of the potential risk to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.4), Use in Specific Populations (8.1, 8.3)].
Advise females of reproductive potential to use effective contraception during treatment with TEVIMBRA and for 4 months after the last dose [see Warnings and Precautions (5.4), Use in Specific Populations (8.1, 8.3)].
Lactation
Advise women not to breastfeed during treatment with TEVIMBRA and for 4 months after the last dose [see Use in Specific Populations (8.2)].
Manufactured by:
BeOne Medicines USA, Inc.
Pennington, NJ 08534
U.S. License No. 2400
TEVIMBRA® is a registered trademark owned by BeOne Medicines I GmbH or its affiliates.
© BeOne Medicines I GmbH, 2026. All Rights Reserved.